证券代码：839729 证券简称：永顺生物 公告编号：2025-007 广东永顺生物制药股份有限公司 第五届董事会第九次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 4 月 25 日 2.会议召开地点：广东省现代农业集团有限公司二楼会议室 3.会议召开方式：现场表决 4.发出董事会会议通知的时间和方式：2025 年 4 月 15 日以书面方式发出 5.会议主持人：董事长谭德明 6.会议列席人员：公司监事、公司高级管理人员 7.召开情况合法、合规、合章程性说明： 本次会议的参与表决董事人数、召集、召开程序和议事内容均符合《公司法》、 《公司章程》及相关法律法规的规定，所作决议合法有效。 （二）会议出席情况 会议应出席董事 6 人，出席和授权出席董事 6 人。 二、议案审议情况 （一）审议通过《关于 2024 年度董事会工作报告的议案》 1.议案内容： 根据《公司章程》以及《董事会议事规则》的相关规定，公司董事会总结 ...

证券代码：839729 证券简称：永顺生物 公告编号：2025-013 广东永顺生物制药股份有限公司 公司本次权益分派预案如下：公司目前总股本为 273,350,000 股，以未分配 利润向全体股东每 10 股派发现金红利 1.3 元（含税）。本次权益分派共预计派发 现金红利 35,535,500 元。 公司将以权益分派实施时股权登记日应分配股数为基数，如股权登记日应分 配股数与目前预计不一致的，公司将维持分派比例不变，并相应调整分派总额。 实际分派结果以中国证券登记结算有限责任公司北京分公司核算的结果为准。 二、最近三年现金分红情况 公司合并资产负债表、母公司资产负债表中本年末未分配利润为正值且报告 期内盈利，最近三年已分配及拟分配的现金红利总额（包括以现金为对价，采用 集中竞价方式、要约方式已实施的股份回购金额 28,801,567.63 元共计 188,473,174.35元，占最近三年年均归属于上市公司股东的净利润比例为306.75%, 超过 30%。 三、审议及表决情况 2024 年年度权益分派预案公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并 ...

Financial Performance - Net profit attributable to shareholders for Q1 2025 was ¥7,916,030.82, a decrease of 5.47% year-on-year[8]. - Operating revenue for Q1 2025 was ¥65,456,650.96, down 1.56% from ¥66,495,478.87 in Q1 2024[8]. - The net profit for the first quarter of 2025 is 7,916,030.82, a decrease of 5.48% compared to 8,374,511.51 in the same period of 2024[35]. - The total profit for the first quarter of 2025 is 8,711,054.06, down from 9,420,501.30 in the first quarter of 2024, representing a decline of 7.51%[35]. - The operating profit for the first quarter of 2025 is 8,718,430.12, slightly lower than 9,360,944.99 in the same period of 2024[35]. - Basic and diluted earnings per share remain unchanged at 0.03 for both the first quarter of 2025 and 2024[36]. - The total comprehensive income attributable to the parent company for the first quarter of 2025 is 7,916,030.82, compared to 8,374,511.51 in the first quarter of 2024[36]. Assets and Liabilities - Total assets as of March 31, 2025, reached ¥789,010,699.45, an increase of 3.76% compared to the end of the previous year[8]. - Current assets totaled CNY 601,207,705.58 as of March 31, 2025, up from CNY 564,818,676.77 at the end of 2024, reflecting a growth of 6.45%[31]. - Total assets increased to CNY 789,010,699.45 as of March 31, 2025, compared to CNY 760,429,656.42 at the end of 2024, marking a growth of 3.92%[32]. - Total liabilities rose to CNY 118,259,419.58 as of March 31, 2025, compared to CNY 99,800,423.50 at the end of 2024, indicating a significant increase of 18.43%[33]. - The total liabilities to assets ratio remained stable at 14.99% for both the parent and consolidated entities[8]. Cash Flow - The company's cash flow from operating activities increased by 3.35% to ¥17,062,453.70 compared to the same period last year[8]. - The cash flow from operating activities for the first quarter of 2025 is 17,062,453.70, an increase from 16,510,126.57 in the first quarter of 2024[36]. - The total cash outflow from operating activities in the first quarter of 2025 is 46,336,875.46, compared to 51,340,444.49 in the first quarter of 2024[36]. - The cash inflow from investment activities in the first quarter of 2025 is 120,362,370.26, significantly higher than 46,599,181.42 in the same period of 2024[36]. - The net cash flow from investment activities for the first quarter of 2025 is -46,677,987.64, compared to a positive 15,594,454.42 in the first quarter of 2024[37]. - Cash and cash equivalents decreased to CNY 22,468,586.94 from CNY 36,593,830.46, a decline of 38.67%[31]. - The cash and cash equivalents at the end of the first quarter of 2025 amount to 22,318,586.94, down from 205,772,155.39 at the end of the first quarter of 2024[37]. Shareholder Information - The largest shareholder, Guangdong Provincial Agricultural Group, holds 106,780,769 shares, accounting for 39.06% of the total shares[17]. - The second largest shareholder, Guangdong Agricultural Science Assets Management Co., Ltd., holds 53,872,000 shares, representing 19.71% of the total shares[17]. - The third largest shareholder, Guangdong Academy of Agricultural Sciences Animal Health Research Institute, holds 30,799,999 shares, which is 11.27% of the total shares[17]. - There are no pledges or judicial freezes on shares held by shareholders with more than 5% ownership[19]. - The company has no ongoing litigation, arbitration, or external guarantees during the reporting period[21]. - The company has fulfilled all previously disclosed commitments without any overdue situations[28]. Stock Information - The total number of unrestricted shares decreased from 80,425,041 to 76,825,041, representing a change of -3,600,000 shares, which is a reduction of approximately 4.48%[14]. - The total number of restricted shares increased from 192,924,959 to 196,524,959, reflecting an increase of 3,600,000 shares, which is an increase of about 1.87%[14]. - The total share capital remains unchanged at 273,350,000 shares[14]. - The company implemented a stock incentive plan in 2024, granting 3,600,000 restricted shares to 33 individuals, which is approximately 1.32% of the total share capital[24]. Expenses - The company's financial expenses increased by 89.18% to -¥107,316.35, primarily due to adjustments in financial product structures[10]. - Total operating costs for Q1 2025 were CNY 58,827,999.72, an increase of 2.19% from CNY 57,569,882.86 in Q1 2024[34]. - R&D expenses for Q1 2025 were CNY 5,153,474.56, slightly down from CNY 5,350,715.65 in Q1 2024[34]. - The company experienced a 337.53% increase in other payables, reaching ¥18,352,203.48, mainly due to equity incentive contributions[10]. - Non-recurring gains and losses for the period amounted to ¥2,535,421.70 after tax[12].

Financial Performance - The company's operating revenue for 2024 was CNY 268,985,086.87, a decrease of 14.41% compared to CNY 314,282,861.48 in 2023[22] - The net profit attributable to shareholders for 2024 was CNY 40,143,422.44, down 30.86% from CNY 58,058,744.25 in the previous year[22] - The gross profit margin for 2024 was 58.13%, slightly down from 58.82% in 2023[22] - The company's total revenue for the year was approximately ¥268.99 million, showing a slight decrease of 0.26% compared to the preliminary report[26] - The total profit amounted to approximately ¥44.51 million, reflecting a decline of 2.95% from the preliminary report[26] - The net profit attributable to shareholders was approximately ¥40.14 million, down by 2.74% compared to the preliminary report[26] - The net profit after deducting non-recurring gains and losses was approximately ¥30.99 million, a decrease of 4.17% from the preliminary report[26] - The company's operating revenue for 2024 was 268.99 million yuan, a decline of 14.41% from 314.28 million yuan in 2023, with a gross profit margin of 58.13%[62] - The net profit attributable to shareholders for the reporting period was 40.14 million yuan, down 30.86% from 58.06 million yuan in the previous year, mainly due to a decrease in operating profit and government subsidy income[64] Assets and Liabilities - Total assets at the end of 2024 amounted to CNY 760,429,656.42, a decrease of 3.48% from CNY 787,859,964.71 in 2023[23] - Total liabilities decreased by 16.35% to CNY 99,800,423.50 in 2024 from CNY 119,309,799.39 in 2023[23] - The company's total assets at the end of the reporting period were 760.43 million yuan, a decrease of 3.48% from the beginning of the period[40] - The company's cash and cash equivalents decreased by 77.33% to RMB 36.59 million, while other current assets increased by 89.15% to RMB 382.25 million[54] - The company's cash and cash equivalents at the end of the reporting period amounted to 36.59 million yuan, a decrease of 77.33% compared to the previous year-end of 161.40 million yuan, primarily due to adjustments in the structure of financial products held[57] Cash Flow - The company's cash flow from operating activities increased significantly by 133.52% to CNY 72,536,641.96 in 2024 compared to CNY 31,061,874.03 in 2023[23] - Net cash flow from operating activities increased by 133.52% year-on-year to ¥72,536,641.96[76] - Net cash flow from investing activities decreased by 90.13% year-on-year to -¥150,630,398.53, primarily due to increased investment in transferable certificates[77] Research and Development - Research and development expenses totaled 22.96 million yuan, accounting for 8.54% of operating revenue, with new veterinary drug registrations and clinical trial approvals obtained[42] - The company's R&D expenditure for the current period is ¥22,958,367.13, which represents 8.54% of operating revenue, an increase from 8.17% in the previous period[89] - The company has developed a new cell culture production technology for animal vaccines, which has received national invention patent authorization[32] - The company is developing multiple new veterinary vaccines, including a bivalent inactivated vaccine for swine influenza and a new vaccine for the prevention of hemorrhagic disease in freshwater fish[92][93] - The company has successfully developed a safe and effective inactivated vaccine for porcine epidemic diarrhea, with good immunogenicity and stability[95] Market Performance - Sales of pig live vaccines decreased by 19.92% year-on-year, while sales of poultry inactivated vaccines fell by 10.09%[41] - The company successfully registered 7 products in Vietnam and 2 in Egypt, with overseas revenue exceeding 20 million yuan, a year-on-year increase of 34.31%[44] - The average price of live pigs is projected to increase by 11.8% year-on-year to RMB 16.8 per kilogram in 2024, indicating a recovery in the industry[51] - The market share of non-mandatory immunization veterinary biological products is growing faster than that of mandatory immunization products, with pig biological products sales reaching RMB 7.154 billion in 2023[52] Governance and Management - The company has established a comprehensive governance structure including the shareholders' meeting, board of directors, supervisory board, independent directors, and specialized committees to ensure compliance and operational integrity[198] - The governance mechanism provides adequate protection and equal rights for all shareholders, with online voting options available for minority shareholders to facilitate participation[199] - The company has implemented a stock incentive plan in 2024, granting a total of 3.6 million restricted shares, accounting for approximately 1.32% of the total share capital of 27,335 million shares[149] - The stock incentive plan aims to attract and retain talent while enhancing the company's governance structure[148] - The company has recognized 28 individuals as core employees, aiming to optimize the long-term incentive mechanism[192] Risks and Challenges - The company faces uncertainties in funding for new projects, technology development, and product promotion, which could impact future growth[133][134] - The research and development of veterinary vaccines involves long cycles and high costs, with potential risks from rapid virus mutations affecting new product development[135] - The company's performance is closely tied to the livestock industry's health, with macroeconomic fluctuations and major disease outbreaks posing risks to operations[136] - The company is designated as a key producer of avian influenza vaccines, with sales primarily through government procurement, making it vulnerable to policy changes[137] Social Responsibility - The company has actively participated in rural revitalization efforts, providing high-quality products to farmers and donating CNY 10,000 to support university student volunteer programs[110] - The company has implemented a comprehensive environmental management system, ensuring compliance with national environmental regulations and standards[113] - The company has implemented measures to monitor and manage pollution emissions, with all monitoring data submitted to relevant authorities[114]

中信建投证券股份有限公司 关于广东永顺生物制药股份有限公司 2024 年募集资金存放与实际使用情况的专项核查意见 中信建投证券股份有限公司（以下简称："中信建投证券"、"保荐机构"）作 为广东永顺生物制药股份有限公司（以下简称"永顺生物"或"公司"）向不特 定合格投资者公开发行股票的保荐机构，根据《证券发行与承销管理办法》《北 京证券交易所股票上市规则（试行）》等相关规定，经审慎核查，对永顺生物 2024 年募集资金存放与实际使用情况发表核查意见如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到位情况 经中国证券监督管理委员会证监许可〔2020〕1271 号文核准，并经全国中 小企业股份转让系统有限责任公司同意，公司由主承销商中信建投证券股份有限 公司采用向不特定合格投资者公开发行方式发行人民币普通股（A 股）股票 1,200,000 股，每股面值 1 元，发行价为每股人民币 29.88 元，募集资金总额为 35,856,000.00 元，扣除发行权益性证券直接相关的新增费用 5,170,089.06 元后， 募集资金净额为 30,685,910.94 元。 天健会计师事务所（特殊普通合伙）对本次公 ...

1- 证券代码：839729 证券简称：永顺生物 公告编号：2025-016 广东永顺生物制药股份有限公司 关于向银行申请授信额度的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、申请授信的基本情况 广东永顺生物制药股份有限公司（以下简称"公司"）拟向招商银行股份有 限公司广州分行申请综合授信额度人民币 1 亿元。向上海浦东发展银行股份有限 公司广州分行申请综合授信额度人民币 5000 万元。向中国建设银行股份有限公 司广州天河支行申请综合授信额度人民币 5000 万元。向中国农业银行股份有限 公司广州开发区分行申请综合授信额度人民币 1 亿元。向中国工商银行股份有限 公司广州高新技术开发区支行申请综合授信额度人民币 5000 万元。向中信银行 股份有限公司广州宝岗大道支行申请综合授信额度人民币 1 亿元。向中国民生银 行股份有限公司广州分行申请综合授信额度人民币 5000 万元。向交通银行股份 有限公司广州越秀支行申请综合授信额度人民币 1 亿元。以上授信额度合计人民 币 6 亿元。授信及授 ...

证券代码：839729 证券简称：永顺生物 公告编号：2025-008 广东永顺生物制药股份有限公司 2024 年度独立董事述职报告（任涛） 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 本人任涛，作为广东永顺生物制药股份有限公司（以下简称"公司"）的独 立董事，始终严格遵守《中华人民共和国公司法》《中华人民共和国证券法》《北 京证券交易所股票上市规则》《北京证券交易所上市公司持续监管指引第 1 号— 独立董事》等法律法规、规范性文件以及《广东永顺生物制药股份有限公司章程》 《广东永顺生物制药股份有限公司独立董事工作制度》相关规定，积极履行独立 董事职责，充分发挥独立董事作用，切实维护了公司和股东尤其是中小股东的合 法权益。现将本人 2024 年度履职情况汇报如下： 一、独立董事独立性情况 报告期内，本人任职符合《上市公司独立董事管理办法》《北京证券交易所 上市公司持续监管指引第 1 号——独立董事》规定的独立性要求，本人及本人直 系亲属均不在公司或其附属企业担任除独立董事之外的其他职务，也未在公司主 ...

广东永顺生物制药股份有限公司 非经营性资金占用及其他关联资金往来情况的 专项审计说明 天健会计师事务所 Pan-China Certified Public Accountants 目 录 一、非经营性资金占用及其他关联资金往来情况的专项 审计说明…………………………………………………………第 1—2 页 二、非经营性资金占用及其他关联资金往来情况汇总表………………第 3 页 | | 三、附件……………………………………………………………… 第 | 4-7 | 页 | | --- | --- | --- | --- | | (一) | 本所营业执照复印件……………………………………………第 | 4 | 页 | | (二) | 本所执业证书复印件……………………………………………第 | 5 | 页 | | (三) | 签字注册会计师执业证书复印件……………………………第 | 6-7 | 页 | 非经营性资金占用及其他关联资金往来情况的 专项审计说明 天健审〔2025〕2- 389 号 广东永顺生物制药股份有限公司全体股东： 我们接受委托，审计了广东永顺生物制药股份有限公司（以下简称永顺生物 公司）2024 年度 ...

证券代码：839729 证券简称：永顺生物 公告编号：2025-021 广东永顺生物制药股份有限公司 关于公司使用自有资金购买稳健型理财产品的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 委托理财概述 （二） 委托理财金额和资金来源 理财额度不超过人民币 30,000 万元，资金来源为自有资金。 （三） 委托理财方式 （一） 委托理财目的 根据公司资金预算使用情况，在确保正常经营所需流动资金及资金安全的情 况下，公司拟利用自有资金用于购买稳健型理财产品，以增加公司投资收益。 1、 预计委托理财额度的情形 在确保不影响公司正常经营的前提下，拟在 2025 年度使用不超过人民币 30,000 万元的自有资金购买稳健型理财产品，资金可以滚动使用，但任意时点 购买总额不超过上述额度，且单笔购买金额不超过 3,000 万元。 （四） 委托理财期限 自董事会审议通过之日起至 2025 年 12 月 31 日，如单笔产品的存续期超过 上述决议有效期，则决议的有效期自动顺延至该笔交易终止之日止。 二、 决 ...

证券代码：839729 证券简称：永顺生物 公告编号：2025-025 （二）辞职原因 陈少阳先生因工作调动，申请辞去公司第五届董事会董事职务。 二、上述人员的辞职对公司产生的影响 （一）本次辞职未导致公司董事会成员人数低于法定最低人数，未导致公司监事会成员 人数低于法定最低人数，未导致职工代表监事人数少于监事会成员的三分之一，未 导致董事会中兼任高级管理人员的董事和由职工代表担任的董事人数超过公司董 事总数的二分之一，未导致董事会或者其专门委员会中独立董事所占的比例不符合 相关规则或者公司章程的规定，未导致独立董事中欠缺会计专业人士。 （二）对公司生产、经营上的影响 陈少阳先生辞去公司董事职务后，不会对公司生产经营产生不利影响。 广东永顺生物制药股份有限公司董事辞职公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法律责任。 一、辞职董监高的基本情况 （一）基本情况 本公司董事会于 2025 年 4 月 24 日收到董事陈少阳先生递交的辞职报告，自 2025 年 4 月 24 日起辞职生效。上述辞职人员持有公司 ...